No Data
Health Check: How Prudently Does PharmaResources (Shanghai) (SZSE:301230) Use Debt?
Hongbo Pharmaceuticals (301230.SZ) shareholder Zhongfu Jishi completed a 1% shareholding reduction.
Announcement from Hongbo Pharmaceuticals (301230.SZ), the company's shareholder Peking Zhongfu Jishi Investment Center (Limited Partnership) (referred to as...
Hongbo Pharmaceuticals (301230.SZ) plans to grant 1.23 million restricted stocks at a grant price of 12.35 yuan per share.
Hongbo Pharmaceutical (301230.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft), the company plans to award restricted stocks to incentivize employees, with a total of 400 participants participating.
Hongbo Pharmaceutical: Report for the third quarter of 2024
Hongbo Pharma (301230.SZ) released its performance for the first three quarters, with a net income of 15.2436 million yuan, a 66.81% year-on-year decrease.
Hongbo Medicine (301230.SZ) released the third quarter report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Hongbo Pharmaceuticals (301230.SZ): In the first half of 2024, a dividend of 1 yuan per 10 shares will be distributed. The ex-dividend date is October 24th.
Golden 汇October 17th丨Hongbo Pharmaceutical (301230.SZ) announced that the company's interim equity distribution plan for the first half of 2024 is as follows: based on the total share capital of the company, excluding the repurchased 2,046,200 shares, the remaining 137,540,405 shares will be distributed to all shareholders at a rate of 1.0 RMB cash per 10 shares. The equity registration date is October 23, 2024, and the ex-rights and ex-dividend date is October 24, 2024.
Declining Stock and Decent Financials: Is The Market Wrong About PharmaResources (Shanghai) Co., Ltd. (SZSE:301230)?
